Progenitor Therapeutics, the biotechnology company developing drugs to regenerate tissues of the body, has announced that the Company’s founder, Dr. Yen Choo, has been named “Best CEO in the Stem Cell Industry” by European CEO magazine.
Progenitor Therapeutics is a spin out from Plasticell, a stem cell biotech company also founded by Dr Choo which is best known for its award-winning CombiCult® stem cell platform technology, but is also progressing a therapeutic pipeline chiefly focused on the expansion of hematopoietic stem cells and the manufacture of various high value blood cell types.
Dr. Choo, currently Executive Chairman of Plasticell and CEO of Progenitor Therapeutics, commented: “The group’s therapeutic activities – now split between Plasticell’s cell therapy development and Progenitor’s regenerative drug discovery – has been built up historically with a minimal amount of angel and institutional equity investment (approx. £10m), re-cycling of income from CombiCult® partnerships and more than 15 non-dilutive UK government grants, many of which have successfully delivered multi-million pound projects. In this way, we have managed to diversify and progress our therapeutic pipeline while delivering exceptional shareholder value.”